U.S. Patent Office Grants Renew Biopharma Pivotal Patent for Cannabinoid Biosynthesis
Updated: a day ago
The newly granted patent claims provide exclusive rights to employ the best-known, non-natural amino acid substitutions to NphB. Specifically, for example, amino acid substitutions at site 161 (which are now recognized to be powerful for unlocking the remarkable potential of NphB) are included in the granted claims. Overall, these engineered enzymes will have a significant impact on the efficiency, scale-up and profitability of commercial manufacturing of cannabinoids by fermentation.